Identification of pathways for bipolar disorder: a meta-analysis by Nurnberger, John I. Jr. et al.
Identification of Pathways for Bipolar Disorder A Meta-analysis
John I. Nurnberger Jr, MD, PhD, Daniel L. Koller, PhD, Jeesun Jung, PhD, Howard J. 
Edenberg, PhD, Tatiana Foroud, PhD, Ilaria Guella, PhD, Marquis P. Vawter, PhD, and John 
R. Kelsoe, MD for the Psychiatric Genomics Consortium Bipolar Group
Department of Medical and Molecular Genetics, Indiana University School of Medicine, 
Indianapolis (Nurnberger, Koller, Edenberg, Foroud); Institute of Psychiatric Research, 
Department of Psychiatry, Indiana University School of Medicine, Indianapolis (Nurnberger, 
Foroud); Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism 
Intramural Research Program, Bethesda, Maryland (Jung); Department of Biochemistry and 
Molecular Biology, Indiana University School of Medicine, Indianapolis (Edenberg); Functional 
Genomics Laboratory, Department of Psychiatry and Human Behavior, School of Medicine, 
University of California, Irvine (Guella, Vawter); Department of Psychiatry, School of Medicine, 
Corresponding Author: John I. Nurnberger Jr, MD, PhD, Institute of Psychiatric Research, Department of Psychiatry, Indiana 
University School of Medicine, 791 Union Dr, Indianapolis, IN 46202 (jnurnber@iupui.edu). 
Author Contributions: Drs Koller and Vawter had full access to all of the data in the study and take responsibility for the integrity of 
the data and the accuracy of the data analysis.
Study concept and design: Nurnberger, Koller, Edenberg, Vawter.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Nurnberger, Koller, Jung, Vawter.
Critical revision of the manuscript for important intellectual content: Nurnberger, Koller, Edenberg, Foroud, Guella, Vawter, Kelsoe.
Statistical analysis: Nurnberger, Koller, Jung, Foroud, Guella, Vawter.
Obtained funding: Nurnberger, Vawter, Kelsoe.
Administrative, technical, or material support: Nurnberger.
Study supervision: Koller, Edenberg.
Additional Contributions: We recognize the contribution of thousands of participants, without whom this work would not be 
possible. Stanley Medical Research Institute provided microarray data. Thomas Lehner, PhD, in his capacity as chief of the Genetics 
Research Branch at the National Institute of Mental Health, was instrumental in initiating and planning the sample collection projects 
required for these analyses. Additional acknowledgments can be found at http://www.nature.com/ng/journal/v43/n10/extref/ng.943-
S1.pdf.
Supplemental content at jamapsychiatry.com
Conflict of Interest Disclosures: None reported.
Additional Information: Genotype data from this article for the 10 257 samples can be obtained from the Center for Collaborative 
Genetic Studies on Mental Disorders in accordance with National Institute of Mental Health data release policies (https://
zork5.wustl.edu//nimh/). Genotype data from the Wellcome Trust Case Control Consortium sample can be obtained from http://
www.wtccc.org.uk/info/access_to_data_samples.html. Genotype data from the BOMA–Bipolar Study can be obtained by contacting 
Sven Cichon, PhD (sven.cichon@uni-bonn.de). Data and biomaterials from the National Institute of Mental Health Genetics Initiative 
Molecular Genetics of Schizophrenia control sample were collected by NorthShore University HealthSystem, Evanston, Illinois 
(supported by grant R01MH59571 from the National Institute of Mental Health to Pablo V. Gejman, MD, collaboration coordinator, 
principal investigator) as part of a collaborative R01 application comprising 10 sites. From 2003 to 2006, the principal investigators 
and coinvestigators were the following: NorthShore University HealthSystem, Evanston, Illinois (grant R01 MH59571): Pablo V. 
Gejman, MD (collaboration coordinator, principal investigator), Alan R. Sanders, MD; Emory University School of Medicine, Atlanta, 
Georgia (grant R01MH59587): Farooq Amin, MD (principal investigator); University of California, San Francisco (grant 
R01MH60870): William F. Byerley, MD (principal investigator); University of Iowa, Iowa City (grant R01MH59566): Donald W. 
Black, MD (principal investigator), Raymond R. Crowe, MD;Washington University, St Louis, Missouri (grant R01MH60879): C. 
Robert Cloninger, MD (principal investigator); University of Colorado, Denver (grant R01MH59565): Robert Freedman, MD 
(principal investigator), Ann Olincy, MD; Stanford University, Palo Alto, California (grant R01MH61675): Douglas F. Levinson, MD 
(principal investigator); Louisiana State University, New Orleans (grant R01 MH67257): Nancy G. Buccola, APRN, BC, MSN 
(principal investigator); University of Queensland, Brisbane, Australia (grant R01MH59588): Bryan J. Mowry, MD (principal 
investigator); and Mt Sinai School of Medicine, New York, New York (grant R01 MH59586): Jeremy M. Silverman, PhD (principal 
investigator).
HHS Public Access
Author manuscript
JAMA Psychiatry. Author manuscript; available in PMC 2015 August 03.
Published in final edited form as:
JAMA Psychiatry. 2014 June ; 71(6): 657–664. doi:10.1001/jamapsychiatry.2014.176.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
University of California, San Diego, La Jolla (Kelsoe); Department of Psychiatry, Special 
Treatment and Evaluation Program, Veterans Affairs San Diego Healthcare System, San Diego, 
California (Kelsoe)
Abstract
IMPORTANCE—Genome-wide investigations provide systematic information regarding the 
neurobiology of psychiatric disorders.
OBJECTIVE—To identify biological pathways that contribute to risk for bipolar disorder (BP) 
using genes with consistent evidence for association in multiple genome-wide association studies 
(GWAS).
DATA SOURCES—Four independent data sets with individual genome-wide data available in 
July 2011 along with all data sets contributed to the Psychiatric Genomics Consortium Bipolar 
Group by May 2012. A prior meta-analysis was used as a source for brain gene expression data.
STUDY SELECTION—The 4 published GWAS were included in the initial sample. All 
independent BP data sets providing genome-wide data in the Psychiatric Genomics Consortium 
were included as a replication sample.
DATA EXTRACTION AND SYNTHESIS—We identified 966 genes that contained 2 or more 
variants associated with BP at P < .05 in 3 of 4 GWAS data sets (n = 12 127 [5253 cases, 6874 
controls]). Simulations using 10 000 replicates of these data sets corrected for gene size and 
allowed the calculation of an empirical P value for each gene; empirically significant genes were 
entered into a pathway analysis. Each of these pathways was then tested in the replication sample 
(n = 8396 [3507 cases, 4889 controls]) using gene set enrichment analysis for single-nucleotide 
polymorphisms. The 226 genes were also compared with results from a meta-analysis of gene 
expression in the dorsolateral prefrontal cortex.
MAIN OUTCOMES AND MEASURES—Empirically significant genes and biological 
pathways.
RESULTS—Among 966 genes, 226 were empirically significant (P < .05). Seventeen pathways 
were overrepresented in analyses of the initial data set. Six of the 17 pathways were associated 
with BP in both the initial and replication samples: corticotropin-releasing hormone signaling, 
cardiac β-adrenergic signaling, phospholipase C signaling, glutamate receptor signaling, 
endothelin 1 signaling, and cardiac hypertrophy signaling. Among the 226 genes, 9 differed in 
expression in the dorsolateral prefrontal cortex in patients with BP: CACNA1C, DTNA, FOXP1, 
GNG2, ITPR2, LSAMP, NPAS3, NCOA2, and NTRK3.
CONCLUSIONS AND RELEVANCE—Pathways involved in the genetic predisposition to BP 
include hormonal regulation, calcium channels, second messenger systems, and glutamate 
signaling. Gene expression studies implicate neuronal development pathways as well. These 
results tend to reinforce specific hypotheses regarding BP neurobiology and may provide clues for 
new approaches to treatment and prevention.
It has been known for many decades that bipolar disorder (BP) is substantially influenced by 
genetic factors. Heritability of BP has been estimated at 80% to 85%.1 Models of illness are 
most consistent with multifactorial inheritance. Searches for common variants of moderate 
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effect in candidate gene studies of BP have not produced consistent results. Moreover, 
genome-wide association studies (GWAS) with thousands of samples have not provided 
evidence that such moderate effect variants exist.2-4 However, common variants of small 
effect (odds ratio < 1.2) have been demonstrated and replicated.4 Identification of individual 
gene variants has provided promising leads to the biology of BP, in particular the 
identification of genes coding for calcium channel subunits such as CACNA1C.4,5 Current 
methods estimate that 38% of the phenotypic variance for BP may be explained by the 
cumulative impact of many common alleles of small effect.6 Herein, we attempt to identify 
important components of that variance.
Rare variants of large effect, such as copy number variants, have been suggested to play a 
role in BP susceptibility.7 Although such variants seem unlikely to be as prominent in BP as 
they appear to be in autism and schizophrenia, this area requires additional investigation. 
Genomic methods such as sequencing and methylation studies have been used in BP, but no 
definitive results are yet available.
In addition to specific single genes related to BP, panels of single-nucleotide polymorphisms 
(SNPs) that contain predictive value for BP have been identified.8 Allele scoring methods 
have shown significant similarity not only between independent data sets of patients with BP 
but also between the genetic architectures of schizophrenia and BP.9
It has previously been demonstrated that additional information may be gleaned from 
GWAS by identifying biological pathways. Torkamani et al10 took this approach in BP; 
their analysis of Wellcome Trust Case Control Consortium data using the program 
Metacore, which weights each gene based on the most significant SNP in that gene, 
suggested 5 pathways, including glutamate regulation of dopamine signaling and adrenergic 
mediation of cytoskeletal remodeling. Holmans et al11 applied the method ALIGATOR 
(Association List Go Annotator; based on overrepresentation of pathway genes in lists of 
nominally significant SNPs) to Psychiatric Genomics Consortium 1 (PGC1) data on BP; 
using Gene Ontology (GO) categories, they identified hormonal action, transcriptional 
regulation, and autophagy as important inBP. O’Dushlaine et al12 used the SNP ratio test 
(the ratio of nominally significant to non-significant SNPs in genes from a particular 
pathway) applied to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways to 
identify cell adhesion molecules as likely to be involved in BP. Pedroso et al13 used 
genewise analysis of 3 GWAS data sets combined with brain expression data to identify 
specific genes of interest; they separately identified gene sets involved in particular protein 
interaction subnetworks, specifying association with networks involved with neural 
transmission, Wnt signaling, and Notch signaling. Le-Niculescu et al14 used convergent 
functional genomics, which combines GWAS data with brain expression data and animal 
model results. Their results emphasize growth factors, neurotransmitters, clock genes and 
transcription factors, neuronal metabolism, and neuronal connectivity as central mechanisms 
in BP. In the article by the Psychiatric GWAS Consortium Bipolar Disorder Working 
Group,4 pathway analysis identified a group of calcium channel subunits as being putatively 
involved in BP vulnerability.
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Our study differs from these in some or all of the following ways: (1) targets genes that 
show modest but consistent evidence of association across multiple individual data sets; (2) 
uses an empirical function to correct for gene size; (3) uses the extensively curated Ingenuity 
database of canonical pathways; (4) uses the gene set enrichment analysis (GSEA)–SNP 
method for pathway verification; and (5) compares results with gene expression results from 
an independent study of postmortem dorsolateral prefrontal cortex (DLPFC) from patients 
with BP. We used 4 individual GWAS data sets for our initial sample and an independent 
collection of samples from the PGC as a replication data set. To study brain-relevant 
pathophysiology of BP, we integrated a meta-analysis of gene expression studies from the 
Stanley Medical Research Institute (SMRI) microarray collection15 with the results of 
pathway analysis.
Methods
Association Studies
Ascertainment and Assessment—Each of the 4 individual data sets has been 
previously described and GWAS results have been published.2,3,16,17 Recruitment and 
screening of participants have been described for the Genetic Association Information 
Network,16 the Systematic Treatment and Enhancement Program for Bipolar Disorder,17 the 
German Genome Research Network,2 and the Wellcome Trust Case Control Consortium.3 
Some of the control samples were used in both the Genetic Association Information 
Network and Systematic Treatment and Enhancement Program for Bipolar Disorder original 
analyses, and this overlap was modeled in the simulations described later.
Participants in the replication sample have been described previously.4 Briefly, patients with 
BP type I (or a small fraction of patients with BP type II) mood disorder were ascertained 
through treatment facilities and evaluated with a structured interview (Structured Clinical 
Interview for DSMIV, Diagnostic Interview for Genetic Studies, or Schedule for Affective 
Disorders and Schizophrenia). Studies at each site were approved by local institutional 
review boards, and participants gave written informed consent for genetic studies and for 
data sharing. Characteristics of the initial and replication samples are shown in Table 1.
Molecular Methods—Participants in the 4 initial studies were genotyped using 
Affymetrix or Illumina microarrays, testing 500 000 to 1 million SNPs across the genome. A 
search strategy was used to identify and count SNPs of interest within genes in each of the 4 
sets of GWAS results, with gene boundaries defined by the National Center for 
Biotechnology Information Gene database and extended by 10 kilobases (kb) in the 5′ and 3′ 
directions. For subsequent consideration, genes were required to have at least 2 SNPs with P 
<.05 in at least 3 of the 4 initial GWAS.
Simulations—We performed simulation studies to predict the global empirical false-
positive error rate of this approach as a function of the number of SNPs typed in that gene, 
which is highly correlated with gene size. Genes containing more genotyped SNPs have a 
higher false-positive error rate unless corrected. Twenty-five genes of various lengths were 
selected to represent the range of gene size, with overrepresentation of genes of 5 to 200 kb 
to improve precision for that range (eTable in Supplement). We simulated genotype data for 
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the 4 GWAS samples for these 25 genes using the software Hap-Sample.19 Under the null 
hypothesis of no association, HapMap CEU samples were selected to mimic the sample size 
of case and control participants for each GWAS. The resampling approach takes into 
account the linkage disequilibrium structure of each gene. We also mimicked shared control 
samples between the Genetic Association Information Network and Systematic Treatment 
and Enhancement Program for Bipolar Disorder GWAS. Based on 10 000 replicates, we 
predicted the required number of SNPs atP < .05 for each of the 25 genes to satisfy a gene-
specific false-positive error rate of 5%. We then fit a linear regression model to predict the 
mean SNP number per gene needed for empirical significance for each of the 966 genes as a 
function of the maximum number of SNPs for that gene in the 4 studies (eFigure 1 in 
Supplement). For example, a larger gene might require 15 to 20 SNPs at P < .05 in 3 of 4 
data sets to reach empirical significance.
Pathway Identification—The final list of 226 genes was run on a standard Ingenuity 
Pathway Analysis (Ingenuity Systems Inc). All canonical pathways with a nominal 
significance of P < .05 were included in subsequent analyses. Genes driving the pathway 
results are those in the list of 226 that overlap with the predesignated list of genes in each 
Ingenuity canonical pathway.
Pathway Testing—Canonical pathways identified in the Ingenuity Pathway Analysis 
were tested in an independent replication data set composed of samples in PGC2 (all PGC2 
data sets with complete GWAS information reported by the Psychiatric GWAS Consortium 
Bipolar Disorder Working Group4 plus the Thematically Organized Psychosis Sample 7 
data set). Imputation to generate a common SNP map for the PGC2 studies was performed 
using Impute20 and the Markov Chain Haplotyping (MACH) algorithm21 to provide a final 
data set of 2.5 million SNPs. For computational tractability, a subset of these SNPs 
corresponding to the Affymetrix version 6.0 platform was used for further analyses. 
Pathway testing was performed using the GSEA-SNP method,22 which compares the rank 
order of the set of SNPs in the genes of the pathway among all SNPs in the PGC2 GWAS 
results with the null rank order distribution. A significant shift in the rank order pattern was 
considered evidence of association at the pathway level. The false discovery rate (FDR) was 
estimated against a general pathway set including pathways from GO, KEGG, and other 
sources. In each case, the individual Ingenuity pathway of interest was included in the 
general pathway set to calculate the q value.
Gene Expression in DLPFC of Patients With BP
A prior meta-analysis15 of DLPFC (Brodmann area 46) samples using the SMRI microarray 
collection was queried for expression differences in BP samples as compared with controls 
(https://www.stanleygenomics.org/). The SMRI microarray collection was conducted using 
the same 105 DLPFCRNA samples (extracted at SMRI) and then processed at 6 independent 
laboratories by microarray analysis. The demographic and sample characteristics for 
respective BP cases and controls are as follows: n = 34 and 35; 16 (47.1%) and 26 (74.3%) 
male; mean (SD) age, 44.1 (7.7) and 45.4 (10.7) years; mean (SD) postmortem interval, 38.6 
(18.2) and 29.4 (12.9) hours; and mean (SD) pH, 6.4 (0.3) and 6.6 (0.3).
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Before meta-analysis of individual genes, quality-control filters based on Affymetrix metrics 
and principal component analysis were used to remove statistical outliers. Both within and 
cross-study normalizations were used such that the median expression value for each study 
was equal to 100. In the meta-analysis, expression was compared between BP and controls 
using linear regression models on a gene-by-gene basis adjusting for the demographic terms 
that met the criteria for significance for that gene (pH, sex, age, RNA quality, postmortem 
interval, disease severity, drug use, smoking, and other covariates [upto 23 demographic 
effects]). The fold change and P values for each gene were condensed, when appropriate, 
from multiple probe sets on the microarray platforms by using all probes from each 
microarray study independently. The consensus fold changes and associated 95%confidence 
intervals and P values were reported as a weighted combination of the individual fold 
changes and standard errors of the 6 studies.
From this differential expression meta-analysis of the 6 gene expression studies, there were 
919 genes nominally significant in BP compared with controls after adjustment for 
covariates.
A step-by-step summary of the methods is included in the eBox in the Supplement.
Results
From the 4 data sets in our initial sample (Table 1), we identified 966 genes with at least 2 
SNPs at P < .05 in at least 3 of 4 data sets. Simulation was performed on 25 individual genes 
using simulated data sets representing each of these 4. Results of the simulation are shown 
in the eTable in the Supplement, and the resulting regression function is shown in eFigure 1 
in the Supplement. Using this regression model, 226 empirically significant genes were 
detected and chosen for the pathway gene set analysis (Box). By application of the binomial 
theorem (and an estimate of 20 000 genes in the human genome), we would expect that 11 
of these 226 genes are likely to be false positives (a proportion of 0.048) and the others are 
likely to be true positives.
The pathway analysis identified 17 nominally significant canonical pathways (Table 2 and 
Table 3). These were tested in a replication data set by GSEA along with the total number of 
genes in each of the pathways of interest. Of the 17 pathways, 6 showed significant 
association: corticotrophin-releasing hormone (CRH) signaling, cardiac β-adrenergic 
signaling, phospholipase C (PLC) signaling, glutamate receptor signaling, endothelin 1 
signaling, and cardiac hypertrophy signaling. The 6 significant pathways are shown in Table 
2 and in eFigures 2-7 in the Supplement, with the identified genes highlighted.
It was observed that the 6 significant pathways were tagged in the Ingenuity data set by only 
16 of the 226 genes (Box and Table 4): ARHGEF3, CREBBP, GNG2, ITPR2, PLCG2, 
PLD1, AKAP12, CACNA1C, PDE7B, PPP2R5E, GRM1, GRM7, GLI3, MEF2C, PLA2R1, 
and PLCE1. Many of these genes were present in multiple pathways. Because each of these 
pathways was tagged by multiple genes and because every SNP in every gene in each 
pathway was tested by GSEA in an independent data set, we do not expect that any of the 6 
pathways is a false positive.
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The list of 226 genes was compared with the list of 919 genes that differed in expression 
between DLPFC samples from patients with BP and controls. Nine genes were found to 
overlap: CACNA1C, DTNA, FOXP1, GNG2, ITPR2, LSAMP, NPAS3, NCOA2, and NTRK3 
(Box). We note that 3 of these genes are also in the list of 16 genes driving the pathway 
results described earlier (GNG2, CACNA1C, and ITPR2). The concordance of 3 genes in the 
2 lists is greater than would be expected by chance (odds ratio observed/expected > 4.43, 
goodness-of-fit χ2 P <.005). If we restrict the list of 919 brain dysregulated genes to those 
meeting FDR criteria (n = 26) and then test for overlap with the 226 genes from GWAS, the 
single gene in the 2 lists is CACNA1C.
Discussion
Using GWAS results from a large sample of patients with BP with full genome-wide SNP 
data and imputation (a total of 8760 independent cases and 11 763 independent controls), we 
identified 6 significantly overrepresented pathways: glutamate receptor signaling, PLC 
signaling, CRH signaling, endothelin 1 signaling, cardiac β-adrenergic signaling, and cardiac 
hypertrophy signaling (Table 2). All of these pathways involve signaling, including G 
proteins and second messenger systems, and all except 1 (cardiac β-adrenergic signaling) 
involve nuclear gene regulation. The pathway with the strongest evidence statistically is the 
CRH signaling pathway. The GSEA-SNP analysis also showed the highest proportion of 
pathway genes significantly overrepresented in GWAS results in this pathway (61.5%).
These canonical pathways provide independently defined, functionally clustered sets of 
genes. We have highlighted (1) genes driving the pathway results and (2) genes implicated 
in studies of brain gene expression.
The genes driving the pathway results (n = 16) are listed in Table 4. They include 3 genes 
with dysregulated expression in BP frontal cortex: CACNA1C, GNG2, and ITPR2. They also 
includeDTNA(dystrobrevin, part of the dystrophin complex), FOXP1 (forkhead box 
transcription factor, involved in language impairment), LSAMP (limbic system–associated 
membrane protein, involved in cell adhesion), NPAS3 (transcription factor involved in 
neurogenesis), NCOA2 (activates nuclear hormone receptors), and NTRK3 (neurotrophic 
tyrosine receptor kinase, involved in neuron migration).
The CRH signaling pathway is an index of the hypothalamic-pituitary adrenal system 
(eFigure 2 in Supplement). This stress responsive system is consistently dysregulated in 
studies of mood disorder. Well-described hypothalamic-pituitary-adrenal abnormalities 
associated with mood disorders include increased secretion of cortisol over 24 hours23 and 
decreased suppression of cortisol by dexamethasone in about 50% of patients with major 
depressive disorder24 and specifically in BP.25 Increased plasma cortisol responses to the 
dexamethasone/CRH test have been associated with euthymic BP.26 Molecules driving this 
pathway include PLCγ, inositol trisphosphate (IP3) receptor, and myocyte enhancer factor 2 
as well as the transcription factor GLi3, which has notable influence on development and is 
also involved in corticotropin synthesis.
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The cardiac β-adrenergic signaling pathway (eFigure 3 in Supplement) and the cardiac 
hypertrophy signaling pathway (eFigure 7 in Supplement) are both driven by the presence of 
an L-type calcium channel along with G-protein–coupled second messenger systems. L-type 
calcium channels have been clearly implicated in meta-analysis of the BPGWAS data,4 and 
their prominence in our analysis provides validation of our methods. Carman and Wyatt27 
summarized data showing that pharmacological or dietary manipulation of calcium alters 
mood in patients with BP. Dubovsky and Franks28 described early data on the treatment of 
mania with calcium antagonists; more recent data have been summarized by Casamassima et 
al.29 Grunze et al30 suggested that lamotrigine may act through alteration of calcium 
currents in the cell. Variants in the calcium channel proteinTRPM2have been associated 
with BP.31 Variants in P2RX7, which codes for a calcium stimulated adenosine 
triphosphatase, are also associated with BP.32 Differences in subcortical morphology have 
been reported in patients with BP carrying the CACNA1C risk variant compared with 
controls, and there is also evidence for reduced corticolimbic connectivity in carriers.33 
Calcium channel dysregulation in BP was also supported by the convergent functional 
genomics method.14 The involvement of calcium channels in the genetic predisposition to 
BP is the single most consistent finding in BP genetic studies to date.
Molecules driving the association with the CRH signaling pathway are also driving 
association with the PLC signaling pathway (eFigure 4 in Supplement), including PLC γ, 
IP3 receptor, and myocyte enhancer factor 2. In addition, PLC may produce diacylglycerol 
and IP3. Lithium blocks the conversion of inositol phosphate to inositol and leads to the 
accumulation of IP3. The IP3 system has been related to lithium therapeutic activity.34 
Williams et al35 proposed that inositol was involved in the therapeutic actions of valproic 
acid and carbamazepine as well as lithium. The endothelin 1 signaling pathway (eFigure 6 in 
Supplement) includes several phospholipases with major activity on second messenger 
systems and intracellular metabolism in addition to PLC. These are phospholipase A2, 
which activates the arachidonic acid cascade, and phospholipase D, which hydrolyzes 
phosphatidylcholine to produce phosphatidic acid and choline, the precursor for 
acetylcholine. These phospholipases are important not only inendothelial cells but also in 
neuronal cells. They may play a role in inflammatory responses,36 and inflammation has 
been implicated in the pathophysiology of BP in numerous studies.37
As the major excitatory neurotransmitter in the mammalian central nervous system, 
glutamate signals are relayed by ionotropic and metabotropic (G-protein–coupled) receptors 
from the cell membrane through various second messenger systems (eFigure 5 in 
Supplement). One of the strongest candidate gene findings in BP has been the association 
with D–amino acid oxidase activator (DAOA, also known as G72), which deactivatesN-
methyl-D-aspartate receptors by degrading serine.38 A functional variant in this gene has 
been associated with reduced cortical thickness in schizophrenia.39 Riluzole, a glutamate-
modulating agent, has shown preliminary antidepressant results in an open-label study in 
combination with lithium in patients with BP in the depressed state.40
We believe that our method of pathway identification has certain advantages. We consider 
evidence from multiple GWAS and deliberately focus on associations that are modest but 
consistent, a strategy that has proven successful in prior studies.4,8 We correct for gene size 
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using a permutation procedure to calculate empiricalP values. We also incorporate FDR into 
our pathway assessment procedure. Our results are readily interpretable at the gene and 
pathway levels. To our knowledge, our data set, which includes most of the PGC1 and 
PGC2BP data sets, incorporates and expands on all GWAS data sets used in previously 
published BP pathway studies, except for the PGC article itself.4 We note an emphasis on 
glutamate mechanisms,10,14 hormonal action,11 and calcium signaling4 in our results aswell 
as others. One area not emphasized in our results but noted in others12,14 is that of 
mechanisms of neuronal growth and cell adhesion molecules. This area is prominent in the 
genes that overlap with gene expression results (see earlier) in this study.
Our study has limitations. Our method identifies genes with abnormalities in cis regulation 
(within the gene or promoter) in BP but not genes with abnormalities in trans regulation 
(regulatory changes at distant sites). Future studies should be able to use methods and 
databases that will include trans-regulated abnormalities. We have chosen a threshold (≥2 
SNPs at P < .05 in 3 of 4 data sets) that minimizes false-positive results and includes a 
sufficient number of true-positive results to support pathway detection. This threshold 
provides better power to detect larger genes than smaller genes (<25-50 kb), which are 
underrepresented in the list of 226 we have used for tagging pathways. The pathways 
themselves, however, include small and medium-sized genes as well as larger genes. 
Canonical pathways, while having the advantage of providing a predetermined gene list, are 
based on the existing neurobiological literature as curated by Ingenuity Systems Inc. As data 
sets expand and other pathway sources (KEGG, GO) are used, we expect additional 
biological mechanisms to be discovered and present results to be refined. It is possible that 
some associated variants may be markers for true susceptibility variants in nearby genes. We 
have minimized (but not eliminated) this possibility by using GSEA-SNP, which tests all the 
SNPs in each selected gene, not just those that passed the threshold for gene identification. 
Functional studies and insights from systems biology will be required to determine which 
genes and pathways are truly relevant to BP and what mechanisms are involved. The 
comparison between results from GWAS and gene expression studies using postmortem 
brain samples must be interpreted carefully because of differences in subject ascertainment 
and probable nongenetic causes of some gene expression changes.
Conclusions
In summary, 17 pathways were identified in an initial screen of GWAS data from4 samples 
totaling 5253 BP cases and 6874 controls, of which 6 pathways were verified in an 
independent set of 3507 cases and 4889 controls. The identification of these pathways was 
driven by genes involved in hormone regulation, calcium channel genes, genes involved in 
second messenger systems, and glutamate receptor genes. Nine genes involved in the 
pathway identification were also dysregulated in brain samples from patients with BP. In 
addition to the functions described earlier, these included genes that are involved in neuronal 
development.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Box
List of 226 Genes or Loci Associated With Bipolar Disorder at Empirical 
P< .05
Gene names in bold are those genes driving the pathway results; gene names underlined 
are those genes also significant in the gene expression studies.
A2BP1, AAA1, ABLIM1, ACSS3, ADAMTS12, ADAMTS19, ADAMTS2, AGBL1, 
AGBL4, AKAP12, ANK3, ANKFN1, ANKS1B, ANO3, ARHGEF3, ARL15, ASAP2, 
ASB18, ATXN1, AUTS2, B3GALTL, BAI3, BNC2, C10orf11, C14orf101, C21orf34, 
C6orf105, C8orf34, CA10, CACNA1C, CACNA2D3, CADM2, CAMTA1, CDH18, 
CDKAL1, CGNL1, CHST11, CMIP, CMYA5, CNBD1, CNTN3, CNTN6, CNTNAP2, 
COL13A1, COL1A2, COL28A1, CREBBP, CSMD1, CTNNA3, CYP4Z1, CYTSB, 
DCC, DGKB, DGKH, DGKI, DIS3L2, DLG2, DOCK2, DPP10, DTNA, DYRK1A, 
ELMO1, ELOVL2, EML1, ENPP2, EYS, FAM107B, FAM171A1, FAM184A, FBN2, 
FBXL17, FBXO18, FGF12, FHOD3, FLJ30838, FLJ41278, FLJ46010, FOXN3, 
FOXP1, FRMD6, FRY, FUT9, FYB, GFRA1, GLI3, GNG2, GNPTAB, GOLSYN, 
GPC5, GPC6, GPR1, GREM2, GRM1, GRM7, HHAT, HTR2A, IQGAP2, ISPD, 
ITGBL1, ITIH5, ITPR2, KCND2, KCNMA1, KIAA1797, KIFAP3, KIRREL3, 
LAMC2, LASS6, LGMN, LHPP, LMBR1, LOC100129633, LOC100132891, 
LOC100288428, LOC100505875, LOC100506027, LOC100506072, LOC100506380, 
LOC100506403, LOC100507421, LOC400794, LOC642924, LOC643542, LRP2, 
LRRC16A, LRRC3B, LRRTM4, LSAMP, MAD1L1, MAML3, MAN1C1, MAST4, 
ME1, MEF2C, MGC27382, MKL1, MPP7, MTHFD1L, MYBPC1, MYO5B, MYOM2, 
NALCN, NAV2, NCAM1, NCOA2, NOS1AP, NPAS3, NPSR1, NRXN3, NT5DC1, 
NTRK3, ODZ4, OTUD7A, PAK7, PALLD, PAN3, PCGF5, PCNXL2, PCSK2, PDE7B, 
PDZRN4, PHACTR1, PHF21A, PHF21B, PLA2R1, PLCE1, PLCG2, PLD1, 
PLEKHG1, POU2F1, PPFIBP1, PPP1R1C, PPP2R5E, PTGIS, PTPRR, PTPRT, 
RALGAPA2, RBPMS, RFX2, RGS6, RGS7, ROR1, RP1-21O18.1, RP3- 398D13.1, 
SATB2, SEMA3C, SEMA5A, SEZ6L, SGCG, SGMS1, SHANK2, SIAH3, SIK3, 
SLC10A7, SLC2A13, SLIT3, SMG6, SNTB1, SNX29, SORCS2, SPATS2L, SPTLC3, 
SRGAP3, ST7, STK24, STK4, SYN3, SYNE1, SYT14, tcag7.1213, TCF7L1, THSD4, 
THSD7A, TMEM108, TRDN, TRPV3, TSPAN18, TULP4, ULK4, VAT1L, VAV3, 
WDFY4, WDR72, ZCCHC17, ZNF236, ZNF385B
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Table 1
Genome-Wide Association Studies in Bipolar Disorder Included in Pathway Analysis
Sample Cases, No. (n = 8760) Controls, No. (n = 11 763)
Initial sample 5253 6874
 GAIN EAa 1152 1152
 GGRF 772 876
 STEP-BD/UCLa 1461 2008
 WTCCC 1868 2838
Replication sample 3507 4889
 Fran 451 1631
 Ftg2b 1914 1114
 Sw34 825 2084
 TOP7c 317 60
Abbreviations: Fran, French National Sample4; GAIN EA, Genetic Analysis Information Network European-American sample15; GGRF, German 
Genome Research Foundation2; STEP-BD/UCL, Systematic Treatment Enhancement Program for Bipolar Disorder/University College London17; 
Sw34, Swedish National Samples 3 and 44; TOP7, Thematically Organized Psychosis Sample 7; WTCCC, Wellcome Trust Case Control 
Consortium.3
a
There is overlap between the GAIN EA control sample and the STEP-BD control sample (both used the National Institute of Mental Health 
Genetics Initiative control sample described by Sanders et al18; the overlap between the 2 groups was modeled in the simulations carried out for 
this study).
bCombination of Fast STEP2 (a second sample from the Systematic Treatment Enhancement Program for Bipolar Disorder) and TGEN 
(translational genomics sample from the Bipolar Genome Study), with both samples using the same control group.4
cSample is from Norway and was submitted by Ole A. Andreassen, MD, PhD, to the Psychiatric Genomics Consortium Bipolar Group.
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Table 3
Biological Pathways Significant in the Initial Data Set Only and Their Association With Bipolar Disorder
Pathway
P Value in 
Initial Data Set Genes Driving Pathway Results
Phospholipid degradation <.001 DGKH, PLCE1, PLCG2, PLA2R1, DGKB, DGKI, PLD1
Glycerophospholipid metabolism <.001 DGKH, PLCE1, PLCG2, PLA2R1, ELOVL2, DGKB, DGKI, PLD1
Protein kinase A signaling <.001 AKAP12, HHAT, PLCE1, PDE7B, GLI3, ITPR2, PLCG2, 
CREBBP, DCC, TCF7L1, GNG2
CREB signaling inneurons .004 GRM7, PLCE1, GRM1, ITPR2, PLCG2, CREBBP, GNG2
Axonal guidance signaling .006 SLIT3, SRGAP3, GLI3, NTRK3, SEMA5A, DCC, PAK7, SEMA3C, 
GNG2, SHANK2, ABLIM1
Neuropathic pain signaling in dorsal horn neurons .006 GRM7, PLCE1, GRM1, ITPR2, PLCG2
Synaptic long-term depression .02 GRM7, GRM1, ITPR2, PLA2R1, PPP2R5E
Fcγ receptor–mediated phagocytosis in 
macrophages and monocytes
.03 VAV3, DGKB, FYB, PLD1
Sonic hedgehog signaling .04 GLI3, DYRK1A
Glycine, serine, and threonine metabolism .047 PLCE1, PLCG2, ELOVL2
Abbreviation: CREB, cyclic adenosine monophosphate response element–binding protein.
JAMA Psychiatry. Author manuscript; available in PMC 2015 August 03.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Nurnberger et al. Page 18
Table 4
Function of Genes Driving the Pathway Results
Gene Function
CREBBP Transcription factor
GNG2 Guanine nucleotide binding protein
ITPR2 IP3 receptor
PLCG2 Production of IP3 and DAG
PLD1 Phospholipase producing choline
AKAP12 Anchor/scaffold protein, binds PKA
CACNA1C Calcium channel subunit
PDE7B Downregulation of cAMP and cGMP
PPP2R5E Protein phosphatase
GRM1 Glutamate receptor involved in activation of PLC
GRM7 Glutamate receptor involved in inhibition of cAMP
GLI3 Zinc finger transcription factor
MEF2C Myocyte enhancer
PLA2R1 PLA2 receptor involved in clearance
PLCE1 Phospholipase that produces IP3 and DAG
ARHGEF3 Activates 2 Rho GTPases, brain expressed in UniGene
Abbreviations: cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; DAG, diacylglycerol; GTPases, guanosine 
triphosphatases; IP3, inositol triphosphate; PKA, protein kinase A; PLA2, phospholipase A2; PLC, phospholipase C.
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